InnaVirVax Press Release at CROI 2013

Shahin Gharakhanian statement in the latest Press Release from InnaVirVax issued during the Conference on Retroviruses, 3-6 March 2013, Atlanta GA, USA.

Reference: Katlama Ch, Launay O, Ho Tsong Fang R, Bodilis H, Calin R, Autran B,  Gharakhanian S, Vieillard V, J Crouzet J, Debré P.  A randomized, placebo-controlled, double-blind, phase I/IIa dose escalation study of an HIV immunotherapeutic vaccine, VAC-3S, directed to the gp41 3S motif of HIV-1. 20th Conference on Retroviruses (CROI), 2013, Atlanta GA, 3-6 March, Poster # 392.

Innavirvax Press Release CROI 05March2013

Share this: